Table 59Strength of evidence: comparative adverse events for oral selective antihistamine versus nasal antihistamine

OutcomeSeverityFavorsa Oral S-AH RDFavorsa Neither RD = 0Favorsa Nasal S-AH RDUSPSTFActive?bPt Blind?Assessor Blind?Risk of BiasConsDirPrecSOE
SedationSevereBerger, 2006850.6GYYY
Gambardella, 1993886.7PNYY
UnspecifiedBerger, 2003841GNYY
Berger, 2006850GYYY
Charpin, 1995865PYYY
Corren, 2005870.6GYYY
MedInconsDirImprecInsuf
HeadacheSevereBerger, 2006850.6GYYY
UnspecifiedBerger, 2003843GNYY
Berger, 2006850GYYY
Charpin, 1995860PYYY
Corren, 2005871.6GYYY
MedInconsDirInprecInsuf
Bitter AftertasteUnspecifiedBerger, 20038411*GNYY
Berger, 2006857.7*GYYY
Corren, 2005872.3GYYY
MedConsDirImprecInsuf
NosebleedsUnspecifiedBerger, 2006850GYYY
Corren, 2005871GYYY
LowInconsDirImprecInsuf

AE = adverse event; S-AH = selective antihistamine; Cons = consistent; Dir = direct; F = fair; G = good; Incons =inconsistent; Imprec = imprecision; Insuf = insufficient; Med = medium; N = no; P = poor; Pt = patient; RD = risk difference; SOE = strength of evidence; USPSTF = U.S. Preventive Services Task Force; Y = yes.

a

Values are not statistically significant unless otherwise indicated. “Favors” indicates avoidance of harm.

b

The process of harms ascertainment was characterized as active, passive, or intermediate as defined in the Methods section.

*

p<0.05, calculated by CER authors.

From: Results

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.